摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-4-morpholinobenzoyl)pyrrolidine-2-carboxylic acid | 1312800-94-4

中文名称
——
中文别名
——
英文名称
(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-4-morpholinobenzoyl)pyrrolidine-2-carboxylic acid
英文别名
(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-4-morpholin-4-ylbenzoyl)pyrrolidine-2-carboxylic acid
(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-4-morpholinobenzoyl)pyrrolidine-2-carboxylic acid化学式
CAS
1312800-94-4
化学式
C23H25ClN2O4
mdl
——
分子量
428.915
InChiKey
UQGBDDHFDJWVNF-RTWAWAEBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    30
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    70.1
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • [EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET MÉTHODES À UTILISER DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES
    申请人:EUROSCREEN SA
    公开号:WO2015078949A1
    公开(公告)日:2015-06-04
    The present invention is directed to compounds of formula (I), useful in treating and/or preventing inflammatory diseases.
    本发明涉及一种化合物,其化学式为(I),用于治疗和/或预防炎症性疾病。
  • [EN] PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43)<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET MÉTHODES POUR APPLICATION AU TRAITEMENT DE TROUBLES MÉTABOLIQUES
    申请人:EUROSCREEN SA
    公开号:WO2011073376A1
    公开(公告)日:2011-06-23
    The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.
    本发明涉及具有式(I)的新化合物,以及它们在治疗和/或预防代谢性疾病中的用途。
  • PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43)
    申请人:Hoveyda Hamid R.
    公开号:US20130023539A1
    公开(公告)日:2013-01-24
    The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.
    本发明涉及式(I)的新化合物及其在治疗和/或预防代谢性疾病方面的应用。
  • Substituted pyrrolidines as G-protein coupled receptor 43 agonists
    申请人:Ogeda SA
    公开号:US10017468B2
    公开(公告)日:2018-07-10
    The present invention is directed to a process for the preparation of aryl-pyrrolidine carboxylic acid derivative compounds which are useful in treating metabolic diseases, said process consisting of coupling an aryl-pyrrolidine compound with an aryl carboxylic acid compound followed by alkaline or acidic treatment, hydrogenolysis or treatment with a fluoride of the ester intermediate to afford novel aryl-pyrrolidine carboxylic acid derivative compounds.
    本发明涉及一种用于制备治疗代谢性疾病的芳基吡咯羧酸生物化合物的工艺,所述工艺包括将芳基吡咯烷化合物与芳基羧酸化合物偶联,然后对酯类中间体进行碱性或酸性处理、氢解或用化物处理,以得到新型芳基吡咯羧酸生物化合物。
  • PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43)
    申请人:Euroscreen S.A.
    公开号:EP2513053A1
    公开(公告)日:2012-10-24
查看更多